PEGylated staphylokinase SY161
in phase II clinical trials (2002) for treating acute myocardial infarction
Also Known As:
staphylokinase SY161, PEG-modified
Networked: 0
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results